![]() |
|
On 14-15 June 2022, at the International Plasma Protein Congress, policymakers, stakeholders, patient groups and industry come together to discuss the need to increase plasma collection in Europe to facilitate patient access to plasma-derived medicinal products (PDMPs). This year, the congress takes place in Berlin and will be opened by the German Minister of Health discussing German plasma collection and PDMP ecosystem. On day 1, we will look into how plasma collection is organised in many and partnerships between national authorities and the private sector to increase plasma collection in a country. We also explore how forthcoming changes to EU legislation could help Europe reduce its dependency on third countries for plasma. On day 2, we look into the value that PDMPs bring to patients and society and the clinical need for PDMPs and how patient access can be optimised. We see how within regulatory policy, there are many opportunities to improve availability of plasma and access to PMDP; for example, with a mutual recognition agreement on GMP inspections for PDMPs and plasma. And finally, given that safety of PDMPs, next to donor safety, is in the core of our mission, we will have an expert panel discuss the latest developments in pathogen safety and pathogen reduction in PDMPs, such as SARS-COV-2 and vCJD. With the imminent revision of EU legislation such as the Blood Directive and General Pharmaceutical legislation and given the EU’s path towards strategic autonomy around critical medicines, we have a historic opportunity to increase availability of plasma and patient access to PDMPs. Join us at the congress for these important discussions and great networking. |
Time (CET) |
|
07:00-17:30 | On-site registration open |
08:30-09:00 |
Opening - Revising EU Legislation: A One-Off Opportunity to Increase Plasma Collection? |
|
Welcome Opening speech |
09:00-10:45 | SESSION 1 : Paving the Way in Europe Plasma Collection in Germany - Tried and Tested: A success story? CHAIR: Dr. Stephan Walsemann - Scinomed GmbH |
Germany has a well-functioning plasma collection system based on the co-existence and cooperation of all plasma collection stakeholders (ARGE Plasmapherese). Nevertheless, even well-functioning systems need regular updates to meet current and future needs. | |
|
Historic Overview - Presentation Pros and Cons Panel Discussion - Industry perspective Pros and Cons Panel Discussion - Patient Perspective Pros and Cons Panel Discussion - Policy Perspective Pro and Cons Panel Discussion - Donor Perspective Pros and Cons Panel Discussion - Industry perspective |
10:45 -11:30 | Networking Break |
An opportunity for attendees to network with meeting participants, speakers, and sponsors. |
|
11:30-13:00 | SESSION 2: Plasma collection models: Public and Private Sectors: Coexistence, partnership or silo - Seeking the optimum model CHAIR: Alexa Wetzel, Director, Lead for European Plasma - PPTA |
There are different blood and plasma collection systems worldwide. There is no one-size-fits-all model. Every country has its own health system structure. There is no single solution to ensure stable and safe access to plasma-derived medicinal products for patients. This is why in this session we are presenting different collection models, providing examples within the framework of either a public or a public-private coexistence structure. | |
|
Plasma collection in Hungary Plasma collection in Egypt Plasma collection in Ukraine Plasma collection in the United Kingdom |
13:00-14:15 | Networking Lunch |
An opportunity for attendees to network with meeting participants, speakers, and sponsors. | |
14:15-15:45 | SESSION 3: EU Pharma Strategy - Open strategic autonomy: Could the EU approach to starting materials boost plasma collection in Europe? CHAIR: Leo Cendrowicz - The Independent – i – The Brussels Times |
The EU Pharma strategy calls for strategic autonomy on starting materials for medicines in the EU and a reduction in dependency on third countries. The EU has a reliance of 30% (around 3.8 million liters) on the US. In this session, we will discuss how increasing plasma collection in the EU contributes to the EU's goals of that open strategic autonomy, how it improves patient access to PDMPs, and how the private sector is committed to collecting more plasma in Europe. | |
Stefaan van der Spiegel, Team Leader - Substances of human origin, DG Health & Food Safety – European Commission Matthew Hotchko President - The Marketing Research Bureau Martine Pergent, President - IPOPI David Bell, Chief Innovation Officer & General Counsel - Grifols |
|
15:45-16:15 | Networking Break |
An opportunity for attendees to network with meeting participants, speakers, and sponsors. |
|
16:15-17:30 | SESSION 4: EU Pharma Strategy - Europe's industrial policy Progressing From Plasma to Product Establishing Successful Fractionation Plants: Lessons from the Past and Present CHAIR: Leo Cendrowicz - The Independent – i – The Brussels Times |
With a total of 37 plants, Europe has currently one of the strongest plasma fractionation plant footprints in the world. However, there remain European countries that do not at present have their own fractionation plants, but who plan to set them up. Through utilising their own plasma resources, the aim is to control the manufacture of PDMPs in their own country. Setting up a fractionation plant is, however, very complex, expensive and time-consuming. This interactive session strives to discuss aspects of how to be successful and how to avoid failure, amidst the myriad challenges to the availability of sufficient plasma in the EU, not least due to the pandemic. | |
|
Patrick Robert, Consultant - The Marketing Research Bureau Radosław Sierpiński, President of Medical Research Agency, Prime Minister's High Representative for Development of Biotechnology - Poland Peter Janssen, Executive Vice President CDMO Business / GM Belgium - Prothya Biosolutions |
17:30-17:45 | End of the day closure - Hilfenhaus Award Presented by Oliver Schmitt, Chair - PPTA EU Advisory Committee; General Manager - CSL Behring |
17:45-19:15 | Networking Reception |
An opportunity for attendees to network with meeting participants, speakers, and sponsors. |
Time (CET) |
|
08:00-12:00 | On-site registration open |
09:00 - 09:30 |
Opening |
|
Welcome Keynote address |
09:30 - 10.45 | SESSION 5 : EU Pharma Strategy - A Vision Beyond the legislation Improving the Access Pathway for Plasma Protein Therapies CHAIR: Tomasz Kluszczyński Partner - Vintura |
One of the EU’s Pharmaceutical Strategy key objectives is to ensure access to critical medicines for patients, including plasma-derived medicinal products (PDMPs). These medicines are unique biological therapies derived from human plasma and are used to treat patients (300,000 in Europe) with rare, often genetic, life-threatening conditions. Immunoglobulin (IG) therapies, which are used to treat dysfunctional immune systems, represent a lead product category amongst PDMPs. Patients are, however, facing access challenges and a debate on prioritisation and optimising the use of IG has already begun. Restricting patient access would lead to lower socio-economic benefits and is not the solution to an ever-growing clinical need. This session provides a timely opportunity to reflect on how to take up this debate. Healthcare professionals, authorities, together with patients and industry representatives, will share their analyses of the current situation and propose solutions about how to enhance patient access to PDMPs. We will discuss these challenges and opportunities in the context of the EU Pharmaceutical Strategy, which highlights the importance of access to medicines and the goal to reach an EU Open Strategic Autonomy for starting materials for medicines, such as plasma. | |
|
Lieven Annemans, Professor health Economy - UGent Mark Stettner, Senior Consultant, Neurologist and Associate professor - Department of Neurology, University of Essen Martin van Hagen, Head of Clinical Immunology, Internal Medicine/Immunology - University Medical Center Rotterdam Jean Philippe Plançon - EPODIN César Hernández García, Head of Department, Department of Medicines for Human Use - Spanish Agency for Medicines and Health Products (AEMPS) Roberto Tana, Global Marketing Director | International Contract Manufacturing Director - Kedrion Biopharma |
10:45 -11:30 | Networking Break |
An opportunity for attendees to network with meeting participants, speakers, and sponsors. |
|
11:30 - 12:45 | SESSION 6: EU files: The Uniqueness of Plasma - An Essential Differentiation from Blood from a Policy Perspective CHAIR: Faraz Kermani, Head Global Communications - PPTA |
In view of the ongoing revision of the EU general pharmaceutical legislation and blood Directive, this session aims to highlight how having clear definitions and differentiating between blood for transfusion and plasma for manufacturing could enhance access to PDMPs for patients. Using specific examples from the relevant regulatory provisions in the EU Blood Directive and the general EU pharmaceutical legislation, this session will highlight how specific provisions in the EU legislation would reduce regulatory uncertainty, make more plasma available for manufacturing of plasma-derived medicinal products (PDMPs), ultimately benefitting patients in the EU. | |
|
ECJ decision and how legal definitions are outlined in other legal frameworks How better definitions could ensure global cooperation Industry perspective, current hurdles and need for a global collaboration Patient perspective, the importance of differentiation to increase patient access Policymaker’s perspective in the context of the EU files revision |
12:45 - 14:00 | Networking Lunch |
An opportunity for attendees to network with meeting participants, speakers, and sponsors. | |
14:00- 15:20 | SESSION 7: Improving Pathogen Safety - Key Highlights and Developments CHAIR: Dominika Misztela, Senior Director Lead for European Regulatory & Quality - PPTA |
This expert session will address the importance of constant pathogen safety vigilance for the plasma industry and highlight key regulatory decision making and challenges, showcasing UK plasma as an example. | |
Emerging viruses, and consequences for the safety and efficacy of plasma products Anti-SARS-COV-2 antibodies in IG preparations and therapeutic implications The curious case of UK plasma Mission and role of Arbeitskreis Blut: Pathogen Safety of Blood Components |
|
15:20- 15:30 | Closure of IPPC 2022 |
Registration for the IPPC includes access to all general sessions, the exhibit hall, and the Awards Reception on 14 June (you must be registered for the IPPC in order to attend the Awards Reception). Individuals not registered for the IPPC will be given the opportunity to register on-site or will not be granted access to these events.
Registration type PPTA Members Non-members Emeritus Patient representatives, Government, and Health care providers * |
Early bird rate €1200 €1700 €500 No cost* |
After 7 April 2022 €1400 €1900 €500 No cost* |
On-site €1500 €2000 €600 No cost* |
*Complimentary registration subject to verification
Early Bird registration: Payment must be received by 7 April 2022 in order to receive the discounted rate. Registration type: PPTA reserves the right to confirm registration type and charge appropriately. Substitutions: Substitutions will not be allowed on-site. Notification of substitutions must be received by 6 June 2022. Cancellations: Cancellations must be received in writing by 6 June 2022 and will be subject to an administrative fee of 250 €. Cancellations after 6 June 2022 will not be refunded. Full refunds will be provided should the meeting be cancelled due to extenuating circumstances which prohibit the Congress from taking place, including but not limited to the coronavirus pandemic. Press: All press must apply for credentials prior to the event. Please contact Faraz Kermani for more information. Data protection: The personal information provided will be used for PPTA purposes only. |
The International Plasma Protein Congress will be held at the:
Berlin Marriott Hotel
Inge-Beisheim-Platz 1 Berlin, Germany 10785
Tel: +49 30 220000
Reservations
The Berlin Marriott Hotel is offering a special rate for IPPC attendees of 250-270 EUR/night (plus tax) for the dates of 11 June to 16 June 2022. This special rate is available through 13 May 2022 or until the PPTA room block is sold out, whichever occurs first.
Additional information
The Berlin Marriott Hotel is located 40km (25mi) from the Berlin Brandenburg Airport, approximately 35-minute taxi drive.
Take advantage of the premier opportunity to effectively position your brand with key leaders of the plasma protein therapeutics industry. The International Plasma Protein Congress (IPPC), to be held on 14 and 15 June 2022 at the Berlin Marriott Hotel, in Germany, offers a variety of opportunities to expand your reach.
Deadline to register as a Sponsor/Exhibitor is 8 April 2022
PPTA provides each company exhibiting with:
Sponsor Recognition:
Amenities package includes: skirted table, two chairs, waste basket, and electricity.
Booth Traffic Generation Programme: This is an incentive programme to draw attendees to your booth. Attendees will visit each booth to obtain vendor signature and will be entered into a draw to win an Apple Watch! The winner will be announced during the closing announcements on 15 June 2022.
50% discount is offered to the Plasma Protein Forum (PPF) Diamond Sponsors
20% discount is offered to the PPF Platinum Sponsors
Gold level includes:
Silver level includes:
The Congress draws attendees to your exhibit with these scheduled events. This schedule is indicative and is subject to change until the final program is available.
Monday, 13 June
|
Time (CET) |
Exhibitor Move-in | 16.00 – 21.00 |
Tuesday, 14 June
|
Time (CET) |
Exhibit Hall Hours |
|
Wednesday, 15 June
|
Time (CET) |
Exhibit Hall Hours |
|
Please select your 1st, 2nd, and 3rd choice on the registration form.
Increase your visibility at the Congress with these high visibility, high impact opportunities.
All Networking Sponsors will receive:
Sponsor the opening night reception. At the Congress’s most attended event, your company will maximise exposure among attendees.
Increase your visibility at the Congress by sponsoring the lunch on day one and/or day two!
Attendees flock to networking breaks and that means your company gets noticed. There are a total of 4 breaks during the Congress. Choose one, or choose them all!
Product sponsorships are walking billboards for your company. All sponsored products are distributed to every attendee and feature your company name and/or logo alongside (if space permits) the Congress logo. Reserve early, limited availability. For production planning purposes the deadline to submit your branded logo is 15 April 2022.
All Product Sponsors will receive:
Item |
Due Date |
Registration Form and Payment |
8 April |
Logo for branded product |
15 April |
Company Logo and a brief Word Description |
29 April |
Vimeo or YouTube Link |
29 April |
Flyers/Brochures |
Must arrive by 8 June to PPTA Brussels Office: PPTA, Boulevard Brand Whitlock 114/4, B-1200 Brussels, Belgium (Attn: Melanie Conrads) |
“Ship your own” Products |
Must arrive by 8 June to PPTA Brussels Office |
Please fill out and return the sponsorship registration form to Michelle Mason.
PPTA Contacts |
||
Hotel and Congress inquiries: Melanie Conrads or +32.2.724.0188 |
Registration inquiries: Charon Smith or +1.443.433.1114 |
Sponsorship and Exhibit inquiries: Michelle Mason or +1.443.433.1106 |
This detailed video takes viewers through all of the steps a first-time plasma donor would experience during the process of donating lifesaving plasma.
Learn more about the need for plasma donors, plasma donation, and how you can save and improve lives. Find a Donation Center.
"How Is Your Day?" is an initiative to raise awareness of the unique nature of plasma protein therapies and the value they provide to patients. It aims to inform and educate decision makers and the general public worldwide.
Get involved and follow "How Is Your Day?" on social media @HIYDglobal
The need for plasma and plasma donors is more urgent than ever before. Visit givingplasma.org to learn more and to find a donation center near you.